These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 37578897)

  • 21. Small molecules disaggregate alpha-synuclein and prevent seeding from patient brain-derived fibrils.
    Murray KA; Hu CJ; Pan H; Lu J; Abskharon R; Bowler JT; Rosenberg GM; Williams CK; Elezi G; Balbirnie M; Faull KF; Vinters HV; Seidler PM; Eisenberg DS
    Proc Natl Acad Sci U S A; 2023 Feb; 120(7):e2217835120. PubMed ID: 36757890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lecanemab in Early Alzheimer's Disease.
    van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
    N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-Based Discovery of Small-Molecule Inhibitors of the Autocatalytic Proliferation of α-Synuclein Aggregates.
    Chia S; Faidon Brotzakis Z; Horne RI; Possenti A; Mannini B; Cataldi R; Nowinska M; Staats R; Linse S; Knowles TPJ; Habchi J; Vendruscolo M
    Mol Pharm; 2023 Jan; 20(1):183-193. PubMed ID: 36374974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structures of α-synuclein filaments from human brains with Lewy pathology.
    Yang Y; Shi Y; Schweighauser M; Zhang X; Kotecha A; Murzin AG; Garringer HJ; Cullinane PW; Saito Y; Foroud T; Warner TT; Hasegawa K; Vidal R; Murayama S; Revesz T; Ghetti B; Hasegawa M; Lashley T; Scheres SHW; Goedert M
    Nature; 2022 Oct; 610(7933):791-795. PubMed ID: 36108674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of N-terminal Acetylation on the Aggregation of Disease-related α-synuclein Variants.
    Bell R; Castellana-Cruz M; Nene A; Thrush RJ; Xu CK; Kumita JR; Vendruscolo M
    J Mol Biol; 2023 Jan; 435(1):167825. PubMed ID: 36099961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update.
    McFarthing K; Rafaloff G; Baptista M; Mursaleen L; Fuest R; Wyse RK; Stott SRW
    J Parkinsons Dis; 2022; 12(4):1073-1082. PubMed ID: 35527571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinetic profiling of therapeutic strategies for inhibiting the formation of amyloid oligomers.
    Michaels TCT; Dear AJ; Cohen SIA; Vendruscolo M; Knowles TPJ
    J Chem Phys; 2022 Apr; 156(16):164904. PubMed ID: 35490011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alpha-synuclein seeding shows a wide heterogeneity in multiple system atrophy.
    Martinez-Valbuena I; Visanji NP; Kim A; Lau HHC; So RWL; Alshimemeri S; Gao A; Seidman MA; Luquin MR; Watts JC; Lang AE; Kovacs GG
    Transl Neurodegener; 2022 Feb; 11(1):7. PubMed ID: 35125105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019.
    GBD 2019 Dementia Forecasting Collaborators
    Lancet Public Health; 2022 Feb; 7(2):e105-e125. PubMed ID: 34998485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Amyloid-β Pathway in Alzheimer's Disease.
    Hampel H; Hardy J; Blennow K; Chen C; Perry G; Kim SH; Villemagne VL; Aisen P; Vendruscolo M; Iwatsubo T; Masters CL; Cho M; Lannfelt L; Cummings JL; Vergallo A
    Mol Psychiatry; 2021 Oct; 26(10):5481-5503. PubMed ID: 34456336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of sedimentation, microgravity, hydrodynamic mixing and air-water interface on α-synuclein amyloid formation.
    Zhou J; Ruggeri FS; Zimmermann MR; Meisl G; Longo G; Sekatskii SK; Knowles TPJ; Dietler G
    Chem Sci; 2020 Mar; 11(14):3687-3693. PubMed ID: 34094057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural insights into α-synuclein monomer-fibril interactions.
    Kumari P; Ghosh D; Vanas A; Fleischmann Y; Wiegand T; Jeschke G; Riek R; Eichmann C
    Proc Natl Acad Sci U S A; 2021 Mar; 118(10):. PubMed ID: 33649211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Seeded assembly in vitro does not replicate the structures of α-synuclein filaments from multiple system atrophy.
    Lövestam S; Schweighauser M; Matsubara T; Murayama S; Tomita T; Ando T; Hasegawa K; Yoshida M; Tarutani A; Hasegawa M; Goedert M; Scheres SHW
    FEBS Open Bio; 2021 Apr; 11(4):999-1013. PubMed ID: 33548114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies.
    Linse S; Scheidt T; Bernfur K; Vendruscolo M; Dobson CM; Cohen SIA; Sileikis E; Lundqvist M; Qian F; O'Malley T; Bussiere T; Weinreb PH; Xu CK; Meisl G; Devenish SRA; Knowles TPJ; Hansson O
    Nat Struct Mol Biol; 2020 Dec; 27(12):1125-1133. PubMed ID: 32989305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thermodynamic and kinetic design principles for amyloid-aggregation inhibitors.
    Michaels TCT; Šarić A; Meisl G; Heller GT; Curk S; Arosio P; Linse S; Dobson CM; Vendruscolo M; Knowles TPJ
    Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24251-24257. PubMed ID: 32929030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. α-Synuclein aggregation nucleates through liquid-liquid phase separation.
    Ray S; Singh N; Kumar R; Patel K; Pandey S; Datta D; Mahato J; Panigrahi R; Navalkar A; Mehra S; Gadhe L; Chatterjee D; Sawner AS; Maiti S; Bhatia S; Gerez JA; Chowdhury A; Kumar A; Padinhateeri R; Riek R; Krishnamoorthy G; Maji SK
    Nat Chem; 2020 Aug; 12(8):705-716. PubMed ID: 32514159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structures of α-synuclein filaments from multiple system atrophy.
    Schweighauser M; Shi Y; Tarutani A; Kametani F; Murzin AG; Ghetti B; Matsubara T; Tomita T; Ando T; Hasegawa K; Murayama S; Yoshida M; Hasegawa M; Scheres SHW; Goedert M
    Nature; 2020 Sep; 585(7825):464-469. PubMed ID: 32461689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Million-fold sensitivity enhancement in proteopathic seed amplification assays for biospecimens by Hofmeister ion comparisons.
    Metrick MA; do Carmo Ferreira N; Saijo E; Hughson AG; Kraus A; Orrú C; Miller MW; Zanusso G; Ghetti B; Vendruscolo M; Caughey B
    Proc Natl Acad Sci U S A; 2019 Nov; 116(46):23029-23039. PubMed ID: 31641070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
    Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
    Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SAR by kinetics for drug discovery in protein misfolding diseases.
    Chia S; Habchi J; Michaels TCT; Cohen SIA; Linse S; Dobson CM; Knowles TPJ; Vendruscolo M
    Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10245-10250. PubMed ID: 30257937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.